Pharmacological and emerging therapies in the treatment of chronic angina.
Chronic angina is a common manifestation of ischaemic heart disease. Medical treatments are the mainstay approach to reduce the occurrence of angina and improve patients' quality of life. This Series paper focuses on commonly used standard treatments (eg, nitrates, β blockers, and calcium-channel blockers), emerging anti-angina treatments (which are not available in all parts of the world), and experimental treatments. Although many emerging treatments are available, evidence is scarce about their ability to reduce angina and ischaemia.
Department of Medicine, Hospital Unit West, Herning, Denmark; Department of Clinical Pharmacology, Institute of Biomedicine, Aarhus University, Aarhus, Denmark.
Steen E
SE
Husted
The Program for Advanced Coronary Disease, Division of Cardiology, Duke University and Duke Clinical Research Institute, Durham, NC, USA. Electronic address: ohman001@mc.duke.edu.
E Magnus
EM
Ohman
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D009566:Nitrates / Q000627:therapeutic use; D013678:Technology, Pharmaceutical
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D009566:Nitrates